Areej M. AteyaDepartment of Clinical Pharmacy, Faculty of Pharmacy Ain Shams University Cairo Egypt Faculty of Medicine Institut für Klinische Pharmakologie und Toxikologie, Charité-Universitätsmedizin Berlin GermanyJohn Wiley & Sons, Ltd
WUHAN, March 7 (Xinhua) -- The number of cities and counties in central China's Hubei Province, the center of the COVID-19 outbreak, classified as high-risk has fallen by almost half compared with three days ago, according to local authorities. By the end of Friday, 19 cities and coun...
Patients hospitalized for pneumonia after Covid-19 infection have a higher risk of developing new-onset dementia than other pneumonia patients unrelated to Covid-19, a study showed.A research team of professor Adnan I Qureshi at the University of Missour
COVID-19 survivors were about 35 percent more likely than non-COVID patients to have long-term kidney damage or declines in kidney function, a new study published Wednesday in the Journal of the American Society of Nephrology shows.Photo A close look at media center for APEC meeting World...
A total of 71 patients, who were diagnosed with high-risk NMIBC and on intravesical BCG treatment regularly (induction or maintenance), were enrolled in the study. The patients were classified into two groups depending on whether they were diagnosed with COVID-19 during the pandemic period or ...
9, 2020 (HealthDay News) -- In a graphic illustration of the danger the new coronavirus poses to essential workers in America, a new study shows that as many as 74 million of these workers and their families are at increased risk for COVID-19. It gets worse: Of ...
COVID-19 patients had a 40% to 60% higher risk of ending up back in the hospital or dying in the first 10 days, compared with similar patients treated at the same hospitals during the same months for heart failure or pneumonia. By the end of 60 days, the COVID-19 patients' overall ...
Patients with concurrent tuberculosis (TB) and COVID-19 have a high risk for death, according to a study published online April 26 in PLOS Global Public Health.
We present a series of four high-risk, symptomatic, COVID-19 patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline. Doxycycline is an attractive candidate as a repurposed drug in the ...
with mild-to-moderate COVID-19 who are at high risk of severe illness due to their age or medical conditions—the same kind of patients that the Boston researchers were scrutinizing. The CDC urges doctors to treathigh-risk patientswithin five days rather than waiting for their symptoms to ...